Details of the Drug

General Information of Drug (ID: DM581CS)

Drug Name
CD19 and CD22 CAR-T Cells
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1/2 [1]
leukaemia 2A60-2B33 Phase 1/2 [1]
Lymphoma 2A80-2A86 Phase 1/2 [2]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0W4SM
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN CAR-T-Cell-Therapy(Dual specific) [2]
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease B-cell lymphoma
ICD Disease Classification 2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
2 ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma